Literature DB >> 26589916

Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.

Therese Vu1, Rebecca Austin1, Catherine Paine Kuhn2, Claudia Bruedigam2, Axia Song2, Solene Guignes2, Sebastien Jacquelin2, Hayley S Ramshaw3, Geoffrey R Hill4, Angel F Lopez3, Steven W Lane5.   

Abstract

Entities:  

Keywords:  chronic myeloproliferative disorders; cytokine signaling; hematopoietic stem cell

Mesh：

Substances：

Year:  2015        PMID： 26589916      PMCID： PMC4815732          DOI： 10.3324/haematol.2015.136705

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

Authors:  Xiaohui Lu; Lily Jun-Shen Huang; Harvey F Lodish
Journal:  J Biol Chem       Date:  2007-12-23       Impact factor: 5.157

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.

Authors:  Veena Sangkhae; S Leah Etheridge; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

5.  Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.

Authors:  Jean Grisouard; Takafumi Shimizu; Adrian Duek; Lucia Kubovcakova; Hui Hao-Shen; Stephan Dirnhofer; Radek C Skoda
Journal:  Blood       Date:  2015-01-16       Impact factor: 22.113

6.  Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis.

Authors:  Georg F Weber; Benjamin G Chousterman; Shun He; Ashley M Fenn; Manfred Nairz; Atsushi Anzai; Thorsten Brenner; Florian Uhle; Yoshiko Iwamoto; Clinton S Robbins; Lorette Noiret; Sarah L Maier; Tina Zönnchen; Nuh N Rahbari; Sebastian Schölch; Anne Klotzsche-von Ameln; Triantafyllos Chavakis; Jürgen Weitz; Stefan Hofer; Markus A Weigand; Matthias Nahrendorf; Ralph Weissleder; Filip K Swirski
Journal:  Science       Date:  2015-03-13       Impact factor: 47.728

7.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

8.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Authors:  Ann Mullally; Steven W Lane; Brian Ball; Christine Megerdichian; Rachel Okabe; Fatima Al-Shahrour; Mahnaz Paktinat; J Erika Haydu; Elizabeth Housman; Allegra M Lord; Gerlinde Wernig; Michael G Kharas; Thomas Mercher; Jeffery L Kutok; D Gary Gilliland; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

9.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962

10.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
View more
  4 in total

Review 1.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

2.  Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.

Authors:  Kate H Gartlan; Motoko Koyama; Katie E Lineburg; Karshing Chang; Kathleen S Ensbey; Rachel D Kuns; Andrea S Henden; Luke D Samson; Andrew D Clouston; Angel F Lopez; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood Adv       Date:  2019-10-08

3.  Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

Authors:  Megan Bywater; Steven W Lane; Rebecca J Austin; Jasmin Straube; Claudia Bruedigam; Gabor Pali; Sebastien Jacquelin; Therese Vu; Joanne Green; Julius Gräsel; Lianne Lansink; Leanne Cooper; Shin-Jye Lee; Nien-Tsu Chen; Chung-Wei Lee; Ashraful Haque; Florian H Heidel; Richard D'Andrea; Geoff R Hill; Ann Mullally; Michael D Milsom
Journal:  Leukemia       Date:  2019-11-15       Impact factor: 12.883

4.  HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?

Authors:  Teresa L Ramos; Luis Ignacio Sánchez-Abarca; Alba Redondo; Ángel Hernández-Hernández; Antonio M Almeida; Noemí Puig; Concepción Rodríguez; Rebeca Ortega; Silvia Preciado; Ana Rico; Sandra Muntión; José Ramón González Porras; Consuelo Del Cañizo; Fermín Sánchez-Guijo
Journal:  Oncotarget       Date:  2017-04-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.